Publications by authors named "Martin Michaud"
We conducted a national in-depth analysis including pharmacovigilance reports and clinical study to assess the reporting rate (RR) and to determine the clinical profile of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in COVID-19-vaccinated individuals. First, based on the French pharmacovigilance database, we estimated the RR of PMR and GCA cases in individuals aged over 50 who developed their initial symptoms within one month of receiving the BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCoV-19, and Ad26.COV2.
View Article and Find Full Text PDFArticle Synopsis
- A study compared two ways of giving a medicine called tocilizumab to patients with a disease called Takayasu arteritis (TAK).
- They looked at 109 patients from different countries and found that both methods worked similarly well after 6 months, with about 69% showing improvement.
- However, patients who got tocilizumab as a shot under the skin had a higher chance of getting worse again compared to those who received it through an IV.
Article Synopsis
- The study explores the effectiveness and safety of off-label targeted therapies in patients with rare autoimmune and inflammatory diseases.
- A total of 100 patients were enrolled, primarily middle-aged women, with a variety of targeted therapies being used and a significant proportion still on corticosteroid treatments.
- Results indicated that 56% of patients found the treatment effective, leading to a significant reduction in corticosteroid dosage, while the overall tolerance of these therapies was deemed acceptable despite some serious health incidents.
Background: Portal vein Doppler ultrasound pulsatility measured by transoesophageal echocardiography is a marker of the haemodynamic impact of venous congestion in cardiac surgery. We investigated whether the presence of abnormal portal vein flow pulsatility is associated with a longer duration of invasive life support and postoperative complications in high-risk patients.
Methods: In this multicentre cohort study, pulsed-wave Doppler ultrasound assessments of portal vein flow were performed during anaesthesia before initiation of cardiopulmonary bypass (before CPB) and after separation of cardiopulmonary bypass (after CPB).
Objectives: Excessive and inappropriate production of pro-inflammatory cytokines plays a key role in Still's disease. Janus kinase inhibitor (JAKi) agents mainly block pro-inflammatory cytokine pathways, notably IL-6 and IFN. The objective was to assess the efficacy and safety of JAKi agents in difficult-to-treat systemic JIA or adult-onset Still's disease (AOSD).
View Article and Find Full Text PDFIntroduction: An association of systemic sclerosis (SSc) with cryoglobulin and/or cryofibrinogenemia has been described. However, clinical, biological, morphological and prognostic implications are unknown. The objective of this study was to describe the phenotype and evaluate the prognosis of cryoglobulinemia and/or cryofibrinogenemia in the progression of SSc.
View Article and Find Full Text PDFBackground: Systemic sclerosis (SSc) is associated with a variability of mortality rates in the literature.
Objective: To determine the mortality and its predictors in a long-term follow-up of a bi-centric cohort of SSc patients.
Methods: A retrospective observational study by systematically analyzing the medical records of patients diagnosed with SSc in Toulouse University Hospital and Ducuing Hospital.
Few studies of daily practice for patients with giant cell arteritis (GCA) are available. This French study aimed to describe the characteristics and management of GCA in a real-life setting. Cross-sectional, non-interventional, multicenter study of patients ≥50 years old who consulted hospital-based specialists for GCA and were under treatment.
View Article and Find Full Text PDFArticle Synopsis
- This study evaluates the safety and effectiveness of TNF-α antagonists and tocilizumab in treating Takayasu arteritis (TAK) in 209 patients, primarily young women.
- Results show that both treatment options achieved a high rate of complete response (66% for TNF-α and 70% for tocilizumab) after 6 months, although older age was positively correlated with response while certain baseline symptoms were negatively associated.
- The incidence of treatment relapses and adverse effects was similar for both therapies, indicating that they are equally effective for managing refractory TAK over a median follow-up of 36 months.
Daytime Variation of Clinical Outcome in Cardiac Surgery: A Propensity-Matched Cohort Study.
J Cardiothorac Vasc Anesth
November 2021
Objective: The purpose of the present study was to investigate the hypothesis of a nychthemeral variation in the tolerance to ischemia and reperfusion injury in adult cardiac surgeries.
Design: Retrospective cohort study.
Setting: A single academic center.
Article Synopsis
- - The study analyzed patients with sarcoidosis who exhibited joint involvement, detailing 39 cases of sarcoid arthropathy, with 19 categorized as acute (Lofgren's syndrome) and the rest as chronic, highlighting no significant differences in overall joint involvement between the two groups.
- - Acute sarcoidosis presented more symmetrical joint involvement (100% vs. 70%) and involved wrists and ankles more frequently than chronic sarcoidosis, while skin lesions mainly appeared in acute forms, specifically as erythema nodosum.
- - Treatment for chronic sarcoidosis often included NSAIDs, steroids, hydroxychloroquine, methotrexate, and TNF inhibitors, with a 70% response rate noted
Fabry disease is a frequent lysosomal storage disorder secondary to the deficiency of alpha-galactosidase A enzyme. This X-linked genetic disease realizes progressive and systemic manifestations that affect both male and female. Fabry disease may present as "classical", as "late-onset" or "non-classical" forms.
View Article and Find Full Text PDFObjectives: To assess the efficacy of tocilizumab in patients with Takayasu arteritis (TA).
Methods: We conducted a retrospective multicenter study in 46 TA patients treated with tocilizumab. We analyzed factors associated with response to tocilizumab (assessed using NIH score).
Hydroxychloroquine in Systemic Lupus Erythematosus: Comment on the Article by Muangchan et al.
Arthritis Care Res (Hoboken)
July 2016